AMBS - Most undervalued small cap bio-tech currently trading under a dime. $30M market cap.
Working with Becton Dickinson to develop LymPro, diagnostic test to detect early stage Alzheimers.
The company's patented drug, MANF, already has three orphan indications.
I wonder what the thought process is that made the decision to short AMBS at four cents a rational decision.
Such mistakes can be costly as the shorts are finding out now.
One reasonable scenario for the recent buying is that the news of Marcum taking on Amarantus as a new client made it ways to the Marcum employees.
It's quite common that an accounting firm such as Marcum would update their offices and employees on a regular basis with a list of new clients with a profile of the company.
I can just imagine what a synopsis of Amarantus might have stated: "Micro cap bio-tech with both drug development and diagnostic divisions. Patented drug, MANF, has potential in the areas of Parkinson's, Alzheimer's, diabetes, T.B.I., Retinitis Pigmentosa, and numerous other potential orphan indications. Planned uplisting to the NASDAQ in 2014."
If I worked at Marcum and just heard about Amarantus for the first time I would buy a few shares. Wouldn't you?
Novartis for MANF in the diabetes field is also a possibility.
Uplisting to the NASDAQ in 2014.
So much potential for less than a dime. :)
p.s. Shorts are doomed. :(
Why concern yourself with warrants?
If you think the share price is going to .20 or .50 then buy shares at the open tomorrow. You may be able to get them under a dime.
Which one offers 400% upside within three months? Hint: It's not MNKD.
Which one is likely to have a "big pharma" partner with in three months? Hint: It's not MNKD.
Which one has Dr. Joseph Rubinfeld one of the co-founders of Amgen on its advisory board? Hint: It's not MNKD.
Which one has Dr. Owen Garrick the former Co-Head of Mergers & Acquisitions at Novartis Pharmaceuticals on its advisory board? Hint: It's not MNKD.
I would suspect that a number of his followers are more intelligent than he is. Wouldn't you agree?
Shorts are in trouble.
Jason Napadano said it was worth .20 before the orphan indication for diabetes was announced.